BRCA2 and familial pancreatic carcinoma: Non-platinum alkylating agent mitomycin C has also been reported to possess efficacy in a few cases of metastatic pancreatic cancer patients with germline BRCA2 mutations refractory to platinum and olaparib, but prospective data do not exist [52].